MAKScientific

ABOUT US

cannabinergic compound developmentMAKScientific is a privately held Boston-based company founded in 2004 on the basis of research by Professor Alexandros Makriyannis in the chemistry and biochemistry of the cannabinoid system. The Company is a leader in cannabinergic compound development with the ability to address major unmet medical needs for selected diseases with a clear competitive advantage over present therapies. Our mission is the discovery, development and commercialization of novel therapeutics that modulate the endocannabinoid system: a key regulator of homeostasis.

MAKScientific has extensive expertise in the endocannainoid biochemical pathways and has validated therapeutic targets. These include two known GPCRs (CB1 and CB2) as well as enzymes that are in the modulation of this biochemical system including fatty acid amide hydrolase (FAAH), N-acylethanolamine-hydrolyzing amidase (NAAA), diacylglycerol lipase (DGL), and monoacylglyceral lipase (MGL) as well as the cannabinoid transporter system. The Company has proficiency in medicinal chemistry and drug design and has substantial drug development assets that include a large library of carefully designed druggable cannabinergic compounds as well as advanced preclinical drug candidates for treating metabolic disorders, chronic liver disease, pain, neurodegenerative and inflammatory diseases.  

OUR VISION

MAKScientific will be a leading therapeutic company that brings new and innovative drugs to the market place for human diseases that can be modulated by the endocannabinoid system.

BOARD OF DIRECTORS

Nassos Michas, Chairman.  CEO, Stonington Partners, LLC, former President and CEO Weiss Peck and Greer,  former Chairman Merrill Lynch Banks

Nicholas Bacopoulos, Ph.D.,  President & CEO Mersana Therapeutics, formerly President & CEO, Aton Pharmaceuticals, former President/CSO OSI Pharmaceuticals

Harry H. Penner, Jr., J.D.,  Chairman & CEO Nascent Bioscience, formerly President, CEO and Vice Chairman, Marinus Pharmaceuticals, former President CEO & Vice Chair, Neurogen

Alex Makriyannis, Ph.D., Behrakis Professor of Pharmaceutical Biotechnology, Director of the Center for Drug Discovery, Northeastern University, formerly Distinguished Professor of Medicinal Chemistry, Pharmacology, Molecular and Cell Biology, University of Connecticut, and Director, Center for Drug Discovery, University of Connecticut.

Scientific Advisory Board

Alex Makriyannis, Ph.D., details above

Frank Porreca, Ph.D., Professor of Pharmacology, Department of Pharmacology, University of Arizona

Philip Malan, M.D., Ph.D., Professor of Anesthesiology and Pharmacology, Department of Medicine, University of Arizona

Founder’s Accomplishments

Alexandros MakriyannisProfessor Makriyannis is among the first to define the biochemical pathways of endocannabinoids through the development of highly selective ligands for endocannabinoid targets.  Some of the highlights are:

back to top

HOME | ABOUT US | DRUG PIPELINE | INTELLECTUAL PROPERTY | MEDIA CENTER | CONTACT US | LEGAL